Erratum to: Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer (International Journal of Clinical Oncology, (2017), 22, 3, (494-504), 10.1007/s10147-016-1083-9)

Takeshi Suto, Megumi Ishiguro, Chikuma Hamada, Katsuyuki Kunieda, Hiroyuki Masuko, Ken Kondo, Hideyuki Ishida, Genichi Nishimura, Kazuaki Sasaki, Takayuki Morita, Shoichi Hazama, Koutarou Maeda, Hideyuki Mishima, Hideyuki Ike, Sotaro Sadahiro, Kenichi Sugihara, Masazumi Okajima, Shigetoyo Saji, Junichi Sakamoto, Naohiro Tomita

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the original publication of the article, Fig. 1 was published with incorrect numbers of patients (n). The correct Fig. 1 is given in this erratum.

Original languageEnglish
Pages (from-to)805-806
Number of pages2
JournalInternational Journal of Clinical Oncology
Volume22
Issue number4
DOIs
Publication statusPublished - 01-08-2017

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Erratum to: Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer (International Journal of Clinical Oncology, (2017), 22, 3, (494-504), 10.1007/s10147-016-1083-9)'. Together they form a unique fingerprint.

Cite this